elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37462477-AC155B1F-1167-409C-B28F-7219C3E09282
Q37462477-AC155B1F-1167-409C-B28F-7219C3E09282
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37462477-AC155B1F-1167-409C-B28F-7219C3E09282
Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
P2860
Q37462477-AC155B1F-1167-409C-B28F-7219C3E09282
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37462477-AC155B1F-1167-409C-B28F-7219C3E09282
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ed734269942fa70c853519e01de563f4529b86af
P2860
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.